Business Context and Reporting Period
This Form 8-K, filed on December 8, 2025, reports events occurring on December 7, 2025. Lyell Immunopharma, Inc. (LYEL) presented new clinical and translational data at the 67th American Society of Hematology (ASH) Annual Meeting regarding its lead product candidate, rondecabtagene autoleucel (ronde-cel).
Ronde-cel is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in pivotal development for patients with relapsed and/or refractory large B-cell lymphoma (R/R LBCL). The data cutoff date for the presentation was September 5, 2025.
Key Financial Metrics
This filing is a Current Report (Item 8.01 Other Events) focused on clinical trial updates. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for any financial indicators.
Material Changes and Clinical Data
The filing details efficacy and safety results from 69 CAR T-cell naïve patients with R/R LBCL. The efficacy evaluable population consisted of 47 patients (29 in the third- or later-line setting and 18 in the second-line setting).
Efficacy Results
- Third- or Later-Line (3L+) Setting (29 patients):
- Overall Response Rate (ORR): 93% (27/29).
- Complete Response (CR) Rate: 76% (22/29).
- Durability: 72% of patients with CR remained in CR at 6 months or longer.
- Median Progression-Free Survival (PFS): 18 months.
- Second-Line (2L) Setting (18 patients):
- Overall Response Rate (ORR): 83% (15/18).
- Complete Response (CR) Rate: 61% (11/18).
- Durability: 70% of patients with CR remained in CR at 6 months or longer.
- Median Duration of CR: Not reached.
Safety Profile
- Cytokine Release Syndrome (CRS): No Grade 3 or greater CRS observed. Grade 1 CRS occurred in 32% and Grade 2 in 29% of all 69 patients.
- Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS): One case (4%) of Grade 3 or greater ICANS reported in a patient with high disease burden. No Grade 2 ICANS reported. Median time to resolution was 4 days.
- Mortality: No deaths were determined to be related to ronde-cel administration.
Outlook, Management Commentary, and Risks
Translational Data: The filing highlights that ronde-cel's proprietary manufacturing process enriches for CD62L-positive cells, resulting in a higher proportion of naïve and central memory T cells. Compared to approved CD19 CAR T-cell products (axi-cel and tisa-cel), ronde-cel demonstrated up to a three-fold higher expansion post-infusion and sustained capacity to proliferate and kill tumor cells.
Management Commentary: The safety profile is described as manageable and appropriate for outpatient administration. The data supports the hypothesis that the memory-cell phenotype correlates with robust expansion.
Risks and Contingencies: The filing does not explicitly list new risks or contingencies beyond the inherent risks of clinical development. The patient population was noted as high-risk and heavily pre-treated, with 92% of 2L patients having primary refractory disease.
Investor Verification Checklist
- Verify the full statistical analysis plan and confidence intervals for the reported response rates and survival metrics.
- Confirm the specific inclusion/exclusion criteria for the 2L and 3L+ cohorts to assess comparability with other trials.
- Review the detailed safety data for the single Grade 3+ ICANS case to understand the clinical context and management.
- Assess the timeline for potential regulatory submissions based on these pivotal data points.
- Monitor upcoming financial filings (10-Q/10-K) for cash runway updates, as this 8-K contains no financial data.